Janssen-Cilag Ltd.
🇬🇧United Kingdom
A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 310
- Registration Number
- NCT02712463
An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection
Completed
- Conditions
- Hepatitis C Virus
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 239
- Registration Number
- NCT02597270
Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America
Completed
- Conditions
- LeukemiaNon-HodgkinMultiple MyelomaLymphoidLymphoma
- Interventions
- Other: Multiple Myeloma (MM)Other: Non-Hodgkin's lymphoma (NHL)Other: Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 5443
- Registration Number
- NCT02559583
Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population
Phase 4
Completed
- Conditions
- HelminthiasisAmoebiasis
- Interventions
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT02385058
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
Phase 4
Completed
- Conditions
- SchizophreniaSchizophreniform DisorderSchizoaffective Disorder
- Interventions
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT01855074
A Study of Prophylaxis for Migraine Patients With Topiramate in India
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 209
- Registration Number
- NCT01836874
Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia
- First Posted Date
- 2012-11-14
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT01726335
Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients
Phase 4
Completed
- Conditions
- HIV-1
- Interventions
- Drug: TMC114/ritonavir
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2016-05-23
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT01702090
An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
Phase 4
Completed
- Conditions
- Cancer, Pain
- Interventions
- Drug: Transdermal Therapeutic System (TTS)-Fentanyl
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT00771199
An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery
Phase 4
Terminated
- Conditions
- Pain, Postoperative
- Interventions
- Device: Fentanyl IONSYSDevice: Morphine IV PCA
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Janssen-Cilag Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT00766506
© Copyright 2025. All Rights Reserved by MedPath